On July 13, 2022, at a COVID-19 vaccination site in Olympic Village Street, Chaoyang District, Beijing, medical staff vaccinated an 86-year-old citizen with a COVID-19 vaccine for enhanced shots. Photo by Xinhua News Agency reporter Ju Huanzong
Recently, the reporter learned from the scientific research team of the State Council’s Joint Prevention and Control Mechanism and related scientific research team that my country insists on the parallelization of multiple technical routes, and new progress has been made in the research and development of new coronavirus vaccines.
It is understood that there are three Omickron variants in my country, the unit price of inactivated vaccines in China, , are conducting sequential clinical trials in mainland China, Hong Kong and the UAE, and the trials are currently progressing smoothly. Nine multivalent vaccines involving mutant strains have entered the clinical trial stage, some of which are undergoing phase III clinical trials. At the same time, my country is actively deploying and promoting the research and development of broad-spectrum vaccines.
Recently, another inhaled adenovirus vector vaccine and an recombinant protein vaccine, , were approved, and sequentially strengthened immunity emergency use in prescribed populations six months after completing two doses of inactivated vaccination.
: Inhalation is performed by inhalation by recombinant novel coronavirus vaccine (type 5 adenovirus vector) through oral inhalation, and the inhalation dose is about one fifth of the intramuscular injection dose. The recombinant novel coronavirus fusion protein vaccine has conducted phase III clinical trials. The analysis results of key data of phase III clinical trials show that the recombinant protein vaccine is used to sequentially strengthen immunity on the basis of two inactivated vaccines, which can produce good protective power and have good safety for the new coronary pneumonia (light and above) caused by infection with the Omickron mutant strain.
Experts from the working group of the Vaccine Research and Development Team of the Joint Prevention and Control Mechanism of the State Council said that in the face of the complex epidemic situation, vaccination is still an effective measure for active immunization.
At present, 46 new coronavirus vaccines in my country have entered clinical trials, 21 have been approved for phase III clinical trials overseas, 9 vaccines including inactivated vaccines, adenovirus vector vaccines, and recombinant protein vaccines have been approved for conditional marketing or emergency use, and 3 vaccines have been included in the World Health Organization emergency use list.
(Reporters Tian Xiaohang and Song Chen)
column editor: Qin Hong Text editor: Cao Fei Title picture source: Xinhua News Agency Image editor: Su Wei
Source: Author: Xinhua News Agency
